Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angela C Hirbe

Showing results (21-30 of 93) with videos related to

Pageof 10
Sort By:
Targeted Oncology|July 2, 2024
Malignant Peripheral Nerve Sheath Tumor, a Heterogeneous, Aggressive Cancer with Diverse Biomarkers and No Targeted Standard of Care: Review of the Literature and Ongoing Investigational AgentsNeeta Somaiah, Bishnuhari Paudyal, Robert E Winkler, et al.
BMC Cancer|June 16, 2023
Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromasAmy E Armstrong, Allan J Belzberg, John R Crawford, et al.
Neuro-Oncology Practice|March 9, 2026
Neurogenetic tumor syndromes: The current landscape of workup and treatmentRimas V Lukas, Ashley Cannon, Prashant Chittiboina, et al.
Oncotarget|February 10, 2016
Spatially- and temporally-controlled postnatal p53 knockdown cooperates with embryonic Schwann cell precursor Nf1 gene loss to promote malignant peripheral nerve sheath tumor formationAngela C Hirbe, Sonika Dahiya, Dinorah Friedmann-Morvinski, et al.
Journal of Neuropathology and Experimental Neurology|November 19, 2020
Preferentially Expressed Antigen in Melanoma (PRAME) Expression in Malignant, but Not Benign, Peripheral Nerve Sheath TumorsCathryn R Cadwell, Gul E Yuksek, Angela C Hirbe, et al.
Cancer|November 23, 2016
Clinical genomic profiling identifies TYK2 mutation and overexpression in patients with neurofibromatosis type 1-associated malignant peripheral nerve sheath tumorsAngela C Hirbe, Madhurima Kaushal, Mukesh Kumar Sharma, et al.
Cancer Medicine|July 7, 2019
TYK2 promotes malignant peripheral nerve sheath tumor progression through inhibition of cell deathWenjing Qin, Abigail Godec, Xiaochun Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2025
Reply to: Challenges in Assessing Response in Clinical Trials for Neurofibromatosis Type 1 Plexiform NeurofibromasChristopher L Moertel, Angela C Hirbe, Laura J Klesse, et al.
Neuro-Oncology|March 30, 2018
β-III-spectrin immunohistochemistry as a potential diagnostic tool with high sensitivity for malignant peripheral nerve sheath tumorsAngela C Hirbe, Xiaochun Zhang, Sonika Dahiya, et al.
Neuro-Oncology|December 25, 2013
BRAFV600E mutation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumorsAngela C Hirbe, Melike Pekmezci, Sonika Dahiya, et al.
Pageof 10

Showing results (21-30 of 93) with videos related to

Sort By:
Pageof 10
Targeted Oncology|July 2, 2024
Malignant Peripheral Nerve Sheath Tumor, a Heterogeneous, Aggressive Cancer with Diverse Biomarkers and No Targeted Standard of Care: Review of the Literature and Ongoing Investigational AgentsNeeta Somaiah, Bishnuhari Paudyal, Robert E Winkler, et al.
BMC Cancer|June 16, 2023
Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromasAmy E Armstrong, Allan J Belzberg, John R Crawford, et al.
Neuro-Oncology Practice|March 9, 2026
Neurogenetic tumor syndromes: The current landscape of workup and treatmentRimas V Lukas, Ashley Cannon, Prashant Chittiboina, et al.
Oncotarget|February 10, 2016
Spatially- and temporally-controlled postnatal p53 knockdown cooperates with embryonic Schwann cell precursor Nf1 gene loss to promote malignant peripheral nerve sheath tumor formationAngela C Hirbe, Sonika Dahiya, Dinorah Friedmann-Morvinski, et al.
Journal of Neuropathology and Experimental Neurology|November 19, 2020
Preferentially Expressed Antigen in Melanoma (PRAME) Expression in Malignant, but Not Benign, Peripheral Nerve Sheath TumorsCathryn R Cadwell, Gul E Yuksek, Angela C Hirbe, et al.
Cancer|November 23, 2016
Clinical genomic profiling identifies TYK2 mutation and overexpression in patients with neurofibromatosis type 1-associated malignant peripheral nerve sheath tumorsAngela C Hirbe, Madhurima Kaushal, Mukesh Kumar Sharma, et al.
Cancer Medicine|July 7, 2019
TYK2 promotes malignant peripheral nerve sheath tumor progression through inhibition of cell deathWenjing Qin, Abigail Godec, Xiaochun Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2025
Reply to: Challenges in Assessing Response in Clinical Trials for Neurofibromatosis Type 1 Plexiform NeurofibromasChristopher L Moertel, Angela C Hirbe, Laura J Klesse, et al.
Neuro-Oncology|March 30, 2018
β-III-spectrin immunohistochemistry as a potential diagnostic tool with high sensitivity for malignant peripheral nerve sheath tumorsAngela C Hirbe, Xiaochun Zhang, Sonika Dahiya, et al.
Neuro-Oncology|December 25, 2013
BRAFV600E mutation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumorsAngela C Hirbe, Melike Pekmezci, Sonika Dahiya, et al.
Pageof 10